The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.